Regeneron (NASDAQ:REGN) Pharmaceuticals, known for consistently surpassing earnings expectations, is set to announce its Q3 2023 results on November 2. The company's primary revenue source is Eylea, a medication designed to treat a variety of ophthalmology conditions such as wet age-related macular degeneration, diabetic macular edema, and diabetic retinopathy.
Eylea was co-developed with Bayer AG (ETR:BAYGN) and despite facing competition from other drugs like Avastin and Vabysmo, it has remained a strong performer. The estimated net product sales for Eylea in the U.S., which are managed by Regeneron, stand at $1.55 billion for Q3.
The FDA's approval of aflibercept 8 mg (Eylea HD) in August 2023 has likely contributed to boosting the sales of the drug. This new variant is expected to further solidify Eylea's position in the market.
In addition to Eylea, Regeneron also generates income from the global sales of the asthma drug Dupixent, in partnership with Sanofi (EPA:SASY) (NASDAQ:SNY). The upcoming Q3 results will provide further insights into the performance of both these key products and their impact on Regeneron's financial health.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.